Regulatory approval

Published by the Health Products Regulatory Authority. Approved

Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.

This is written in the approval document.

Citation

Novartis Ireland Limited. Femara 2.5 mg film-coated tablets (Letrozole) [summary of product characteristics]. Health Products Regulatory Authority website. https://assets.hpra.ie/products/Human/22619/Licence_PA0896-012-001_30082024144429.pdf. Revised August 2024. Accessed May 25, 2025.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HPRA (1)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
HPRA (1)	ER positive	Invasive Breast Carcinoma	Letrozole
HPRA (1)	PR positive	Invasive Breast Carcinoma	Letrozole